Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan

Nouso, Kazuhiro; Miyahara, Koji; Uchida, Daisuke; Kuwaki, Kenji; Izumi, Namiki; Omata, Masao; Ichida, Takafumi; Kudo, Masatoshi; Ku, Yonson; Kokudo, Norihiro; Sakamoto, Michiie; Nakashima, Osamu; Takayama, Tadatoshi; Matsui, Osamu; Matsuyama, Yutaka; Yamamoto, Kazuhide

doi:10.1038/bjc.2013.542

Cited by 143 publications

(118 citation statements)

References 19 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…Among the several agents available for HAIC, 5-FU plus CDDP has been the most frequently used in Japan, with a number of reports of favorable results (Table 3) (52)(53)(54)(55)(56)(57)(58), although insertion of an indwelling catheter is essential for this treatment. The reported response rates range from 8% to 86%, and the reported median OS range from 6 months to 33 months.…”

Section: Sorafenib Plus Haic[5-fu + Cddp]mentioning

confidence: 99%

Chemotherapy for hepatocellular carcinoma: current status and future perspectives

Ikeda

Morizane

Ueno

et al. 2017

Japanese Journal of Clinical Oncology

234

154

View full text Add to dashboard Cite

Chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). On the basis of the results of two pivotal Phase III placebo-controlled studies, sorafenib is currently acknowledged worldwide as the standard therapeutic agent for advanced HCC. Following the introduction of sorafenib for the treatment of HCC, Phase III trials of numerous other agents as first-line or second-line chemotherapy have been conducted to determine if any of these agents might offer superior survival benefit to sorafenib. In 2016, a clear survival benefit of regorafenib over placebo was demonstrated in HCC patients showing disease progression after sorafenib treatment. A year later, in 2017, lenvatinib has been shown to be non-inferior to sorafenib, in terms of the overall survival, in chemo-naïve patients with advanced HCC. More recently, promising outcomes have also been reported with new agents, such as nivolumab and cabozantinib. At present, various novel combination regimens including these agents are currently under development. Hepatic arterial infusion chemotherapy (HAIC) is frequently adopted for the treatment of locally advanced HCC in Japan, based on reports of high response rates and favorable long-term outcomes. Although some randomized controlled trials of HAIC plus sorafenib vs. sorafenib alone as first-line therapy have been conducted in patients with advanced HCC, no firm evidence of the superiority of one over the other has been established yet. In the future, demonstration of the survival advantage of HAIC and the recognition of HAIC as one of the standard treatments for patients with advanced HCC are expected.

show abstract

Section: Sorafenib Plus Haic[5-fu + Cddp]mentioning

confidence: 99%

Chemotherapy for hepatocellular carcinoma: current status and future perspectives

Ikeda

Morizane

Ueno

et al. 2017

Japanese Journal of Clinical Oncology

234

154

View full text Add to dashboard Cite

show abstract

“…In addition to fluoropyrimidine (mostly 5-fluorouracil) monotherapy 29 , the combination of 5-fluorouracil and cisplatin has been the most commonly used HAI regimen in HCC (ref. 8,14,16,17,20 ). The efficacy of HAI of 5-fluorouracil/cisplatin combination seems to be higher than HAI of 5-fluorouracil alone 17 .…”

Section: Discussionmentioning

confidence: 99%

“…In a retrospective analysis comparing the outcomes of 476 patients treated with HAI with 1466 patients who did not receive any active therapy, survival was reported to be significantly prolonged in patients treated with HAI (ref. 14 ). Significant survival benefit was still evident when patients treated with HAI were matched with untreated patients using propensity score.…”

Section: Discussionmentioning

confidence: 99%

“…While chemoembolization, another liver-directed procedure targeting the vasculature, is a standard method in the management of patients with inoperable HCC based on the results of prospective trials indicating survival benefit 7 , the utilization of HAI in this setting is less frequent. Numerous studies on HAI in HCC have been reported from East Asia, especially from Japan [8][9][10][11][12][13][14][15][16][17][18][19][20] , but the experience with this approach in the Caucasian population of Western countries is very limited 21,22 . The use of HAI is currently not recommended in therapeutic guidelines, but this approach has been used in the past.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatic arterial infusion in hepatocellular carcinoma: a single center experience

Melichar¹,

Dvořák²,

Ferko³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aim. The aim of the present study was to evaluate a single center experience with hepatic arterial infusion (HAI) in patients with hepatocellular carcinoma. Methods. A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007. Results. Most patients were treated with an HAI of doxorubicin and cisplatin combined with 5-fluorouracil and folinic acid. The response was not evaluable in the majority of patients, predominantly because of associated surgical procedure or because only one cycle of HAI was administered. The median progression-free survival was 7.7 months. The median survival of all patients was 12.2 months (5-year survival 5%). Serious adverse events were observed in 5 patients, and one patient died of liver failure in association with the administration of HAI. Conclusion. The data show the limited efficacy of HAI in patients with hepatocellular carcinoma.

show abstract

“…Besides surgical management, chemotherapy is another important therapeutic option for HCC, but it would cause severe toxicities which are commonly difficult to tolerate by HCC patients [3,4]; for instance, fluorouracil and doxorubicin, two drugs currently used for treating HCC, are not satisfactory since they can produce severe side effects and are not too effective [5]. Thus, searching for new candidate agents with better effectiveness and lower toxicity for treating HCC have received more and more attention.…”

Section: Introductionmentioning

confidence: 99%

Anti-tumor activity of polysaccharides extracted from <i>Senecio scandens</i> Buch, -Ham root on hepatocellular carcinoma

Dou¹,

Zhang²,

Han³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To optimize the extraction conditions of polysaccharides from the root of Senecio scandens Buch,-Ham. (PRS) and evaluate its anti-tumor effect on hepatocellular carcinoma. Methods: Response surface methodology (RSM) applied with a Box-Behnken design (BBD, three levels and three factors) was employed to determine the effect of extraction time, number of extraction and ratio of water to raw material on the yield of PRS. The anti-tumor effect of PRS on A549, HL60, S180 and H22 cell lines was evaluated in vitro by 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) assay, while in vivo anti-tumor effect was evaluated in 20, 40 and 80 mg/kg (p < 0.05, p < 0.05 and p < 0.01, respectively). Treatment with PRS (20, 40 and 80 μg/mL)

show abstract

Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan

Cited by 143 publications

References 19 publications

Chemotherapy for hepatocellular carcinoma: current status and future perspectives

Chemotherapy for hepatocellular carcinoma: current status and future perspectives

Hepatic arterial infusion in hepatocellular carcinoma: a single center experience

Anti-tumor activity of polysaccharides extracted from <i>Senecio scandens</i> Buch, -Ham root on hepatocellular carcinoma

Contact Info

Product

Resources

About